Drugs / PEG-IFNa 2a
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01392170 | Oct 2011 → Mar 2014 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT00437684 | Feb 2007 → Jul 2010 | HIV infectious disease, hepatitis C virus infection | IRCCS San Raffaele | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00437476 Background | Feb 2007 → Jul 2010 | HIV infectious disease, hepatitis C virus infection | IRCCS San Raffaele | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-IFNá-2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01392170 ↗ |
| Route | Subcutaneous | “45 mcg given subcutaneously as a single weekly dose for 24 months.” NCT01392170 ↗ |